Well BTD is a big deal if we are talking money and trials. It’s possible we get a partnership and that could help us speed things along. I know we haven’t taken money from any government funding, but that’s also an option.

For example SNPX is funded by the NIH for
Alzheimer’s, which helped them get through their latest trial without burning too much cash.

So yes as Evil pointed out we continue to de-risk as we get data from other trials or other big news like BTD.

Many companies will dilute share holders right after a price spike and a PR like BTD. That’s also a common way to get money for future trials.

Now as far as dilution, we already have a ton of shares out at this point. Too many IMO. The last thing shareholders want is more dilution. NP is fully aware of this and that’s why he prides himself on it. I give him credit where it’s due. Maybe someday the company will buy back shares making this float smaller.